Kinase targets in CNS drug discovery. (March 2017)

• Record Type: Journal Article
• Authors: Gunosewoyo, Hendra; Yu, Lifang; Munoz, Lenka; Kassiou, Michael
• Is Part Of: Future medicinal chemistry. Volume 9:Number 3(2017)
• Page Start: 303
• Page End: 314
• Publication Date: 2017-03
• Subjects: blood–brain barrier -- brain cancer -- dual-specificity kinase inhibitors -- GSK-3 -- kinase -- LRRK2 -- neurodegenerative diseases; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc-2016-0214
• Languages: English
• ISSNs: 1756-8919

Abstract

Originally thought to be nondruggable, kinases represent attractive drug targets for pharmaceutical companies and academia. To date, there are over 40 kinase inhibitors approved by the US FDA, with 32 of these being small molecules, in addition to the three mammalian target of rapamycin inhibitor macrolides (sirolimus, temsirolimus and everolimus). Despite the rapid development of kinase inhibitors for cancer, presently none of these agents are approved for CNS indications. This mini perspective highlights selected kinase targets for CNS disorders, of which brain-permeable small-molecule inhibitors are reported, with demonstrated preclinical proof-of-concept efficacy. This is followed by a brief discussion on the key challenges of blood–brain barrier penetration and selectivity profiles in developing kinase inhibitors for CNS disorders.